¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦17ȸ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ ¿µ³²Áöȸ ½ÉÆ÷Áö¾ö : 2022-11-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦17ȸ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ ¿µ³²Áöȸ ½ÉÆ÷Áö¾ö : 2022-11-26
±³À°ÀÏÀÚ : 2022-11-26
±³À°Àå¼Ò : °æÁÖ HICO  
±³À°ÁÖÁ¦ : Á¦17ȸ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ ¿µ³²Áöȸ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¿µ³²Áöȸ  
´ã´çÀÚ : Á¶¿¹¸®
¿¬¶ôó : 02-582-8222  
À̸ÞÀÏ :  yehc@kscvi.org      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 6 ½Ã°£ 55ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-26 1F, 101-102È£ 09:00~09:10 2022 ESC(European Society of Cardiology) Guidline Update: Peri-operative Evaluation  ¼Û¿©Á¤(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 09:10~09:20 Big Data Analysis: Coronary Intervention Field  ¹Ú°æ¹Î(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 09:20~09:30 2022 ESC(European Society of Cardiology) Guidline Update: Peri-operative Handling of Antiplatelet Therapy  ¿ÀÁØÇõ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 09:30~09:40 Distal Radial Approach: How to and When?  ÀÌÁø¹è(´ë±¸°¡Å縯ÀÇ´ë) 
Åä·Ð 11-26 1F, 101-102È£ 09:40~10:00 Discussion  () 
È޽Ġ11-26  10:00~10:05 Break  () 
±³À°½Ã°£ 11-26 1F, 101-102È£ 10:05~10:15 FFR(Fractional Flow Reserve) versus QFR(Quantitative Flow Ratio)  ³²Ã¢¿í(°è¸íÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 10:15~10:25 INOCA(Ischemia and No Obstructive Coronary Artery Disease): Is This Real?  °íÁø½Å(°æ»óÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 10:25~10:35 Natural Progression of High Risk Plaque  ÇãÁ¤È£(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 10:35~10:45 Stent Optimization: OCT(Optical Coherence Tomography)-guided  À±ÇõÁØ(°è¸íÀÇ´ë) 
Åä·Ð 11-26 1F, 101-102È£ 10:45~11:05 Discussion  () 
È޽Ġ11-26  11:05~11:20 Coffee Break  () 
±³À°½Ã°£ 11-26 1F, 101-102È£ 11:20~11:32 IVUS(Intravascular Ultrasonography) Based Tip Detection Method in CTO(Chronic Total Occlusion) PCI(Percutaneous Coronary Intervention)  Katsuyuki Hasegawa(Higashi Takarazuka Satoh Hospital Japan) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 11:32~11:44 CTO(Chronic Total Occlusion) PCI(Percutaneous Coronary Intervention) Technique as a Rescue Strategy in a Complicated Situation  Àü±¹Áø(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 11:44~11:56 The Role of Drug-coated Balloon in the Treatment of CTO(Chronic Total Occlusion)  Kazunori Masuda(Uji Tokusyukai Hospital Japan) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 11:56~12:08 Collateral Channel Selection Tool: The J-Channel Score  ÀÌÀåÈÆ(°æºÏÀÇ´ë) 
Åä·Ð 11-26 1F, 101-102È£ 12:08~12:20 Discussion  () 
È޽Ġ11-26  12:20~12:25 Break  () 
±³À°½Ã°£ 11-26 1F, 101-102È£ 12:25~12:45 2022 Korean Lipid Guidelines - Evolocumab for Whom and When?  ÀÌÀåÈÆ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 12:45~13:05 What Is the Role of Empagloflozin Heart Failure Prevention and Treatment?  ±èÁ¤¼ö(ºÎ»êÀÇ´ë) 
Åä·Ð 11-26 1F, 101-102È£ 13:05~13:20 Discussion  () 
È޽Ġ11-26  13:20~13:40 Break  () 
±³À°½Ã°£ 11-26 1F, 101-102È£ 13:40~13:50 The Fate of Angigraphically Significant Stenosis  ¾ÈÁ¾È­(°æ»óÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 13:50~14:00 Peculiar Cause of STEMI(ST-elevation Myocardial Infarction)  ¹Ú°æÀÏ(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 14:00~14:10 Bailout Strategy for Coronary Artery Perforation  È«½ÂÇ¥(´ë±¸°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 14:10~14:20 Musculoskeletal Causes for Chest Pain  À̺´ÁÖ(ºÎ»êÀÇ´ë) 
Åä·Ð 11-26 1F, 101-102È£ 14:20~14:40 Discussion  () 
È޽Ġ11-26  14:40~14:45 Break  () 
±³À°½Ã°£ 11-26 1F, 101-102È£ 14:45~14:55 Catheter Based Management for Acute Pulmonary Thromboembolism  ±èÈ«³â(°æºÏÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 14:55~15:05 Current Status of BPA(Bisphenol A)  ±èµ¿±â(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 15:05~15:15 Update: Management for Complicated Type B Aortic Dissection  ·ùÇö¹Î(Â÷ÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 15:15~15:25 Aorta Complication Following TAVR(Transcatheter Aortic Valve Replacement)  Ãµ¹Î±¸(ºÎ»êÀÇ´ë) 
Åä·Ð 11-26 1F, 101-102È£ 15:25~15:45 Discussion  () 
È޽Ġ11-26  15:45~15:50 Break  () 
±³À°½Ã°£ 11-26 1F, 101-102È£ 15:50~16:00 Hemodynamic Assessment in Patients with Prosthetic Aortic Valve  ¼­Á¤¼÷(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 16:00~16:10 TAVR(Transcatheter Aortic Valve Replacement) in Patient with LV(Left ventricular) Dysfunction  ±è¿õ(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 16:10~16:20 Experience of Transcatheter Edge-to-Edge Repair  ÀÌöÇö(°è¸íÀÇ´ë) 
±³À°½Ã°£ 11-26 1F, 101-102È£ 16:20~16:30 Statistics on Transcatheter Procedure for Structural Heart Disease in Yeongnam Area  ¾çÅÂÇö(ÀÎÁ¦ÀÇ´ë) 
Åä·Ð 11-26 1F, 101-102È£ 16:30~16:50 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦17ȸ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ ¿µ³²Áöȸ ½ÉÆ÷Áö¾ö : 2022-11-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ 2022³â Á¦3Â÷ ÇÁ·ÎÆ÷Æú ÁøÁ¤±³À° : 2022-11-26
´ÙÀ½±Û ´ëÇѺ´¸®ÇÐȸ (¿Â¶óÀÎ)2022³âµµ Á¦3Â÷ ¿¬¼ö±³À°(³»ºÐºñº´¸®) : 2022-11-26
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21212 °æ±â Á¦18ȸ ´ëÇѺ¹¸·¾ÏÇÐȸ Çмú ½ÉÆ÷Áö¾ö : 2024-08-31 0 18 2024-07-02
21211 Àü³² 2024³â ´ëÇѹ̼¼¼ö¼úÇÐȸ Ãß°è Microsurgery Workshop : 2024-08-31 0 19 2024-07-02
21210 ¼­¿ï ´ëÇѽŻý¾ÆÇÐȸ Á¦15Â÷ ±³À°¼¼¹Ì³ª : 2024-08-30 0 14 2024-07-02
21209 ´ë±¸ ´ëÇѾȰúÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö±³À° : 2024-08-27 0 19 2024-07-02
21208 ¼­¿ï 2024³âµµ ´ëÇÑÅëÁõÇÐȸ ¾à¹°Ä¡·á ¿¬¼ö°­Á : 2024-08-25 0 8 2024-07-02
21207 ¼­¿ï °³¿ø 18Áֳ⠱â³ä 2024 °­µ¿°æÈñ´ëÇб³º´¿ø ³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-08-25 0 9 2024-07-02
21206 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ º¹ºÎ& ºñ´¢ ÃÊÀ½ÆÄ °Ë»ç ÀÔ¹®±³À°: °­ÀÇ ¹× ½Ç½À : 2024-08-25 0 8 2024-07-02
21205 ´ë±¸ Á¦3ȸ °è¸í´ëÇб³ µ¿»êº´¿ø ³»°ú ¿¬¼ö°­Á : 2024-08-25 0 12 2024-07-02
21204 °æºÏ Çѱ¹Ãµ½Ä¾Ë·¹¸£±âÇùȸ 2024 Post Graduate Asthma School (2ÀÏÂ÷) : 2024-08-25 0 9 2024-07-02
21203 ¼­¿ï Á¦32ȸ ´ëÇѺñ¸¸°Ç°­ÇÐȸ 2024 Ãß°èÇмú´ëȸ : 2024-08-25 0 11 2024-07-02
21202 ¼­¿ï Á¦14ȸ ¼Ò¾Æ°úÇб³½Ç ¼Ò¾Æ¾Ë·¹¸£±â, È£Èí±âÁúȯ ¿¬¼ö°­Á : 2024-08-25 0 7 2024-07-02
21201 ¼­¿ï ÇѾç´ëÇб³±¸¸®º´¿ø ¼Ò¾Æû¼Ò³â°ú ½Å»ý¾Æ, ¿µÀ¯¾Æ Why & How : 2024-08-24 0 4 2024-07-02
21200 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ ÀÓ»óÁø·áÁöħ Æò°¡À§¿ø º¸¼ö±³À° : 2024-08-24 0 6 2024-07-02
21199 ¼­¿ï ´ëÇѼҾÆÁßȯÀÚÀÇÇÐȸ Á¦ 8ȸ ¼Ò¾Æ±â°èȯ±â ¿öÅ©¼ó : 2024-08-24 0 9 2024-07-02
21198 ¼­¿ï 2024³â ´ëÇѳ»ºÐºñÇÐȸ ´ëÇѼºÈ£¸£¸ó¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-08-24 0 10 2024-07-02
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷